Education
About Us
Working with TipRanks
Follow Us
Orexo AB (ORXOF)
OTHER OTC:ORXOF
ORXOF Stock Chart & Stats
$3.82
-$0.42(-28.00%)
At close: 4:00 PM EDT
$3.82
-$0.42(-28.00%)
Day’s Range― - ―
52-Week Range$1.08 - $4.09
Previous CloseN/A
Volume3.00K
Average Volume (3M)66.00
Market Cap
$94.29M
Enterprise Value$456.23M
Total Cash (Recent Filing)$912.40M
Total Debt (Recent Filing)$492.20M
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Apr 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding34,710,640
10 Day Avg. Volume0
30 Day Avg. Volume66
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.12
Price to Sales (P/S)40.09
P/FCF Ratio6.02
Enterprise Value/Market Cap4.84
Enterprise Value/Revenue1.70
Enterprise Value/Gross Profit-2.93
Enterprise Value/Ebitda-1.65
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.73
Revenue Forecast (FY)$2.35M
Bulls Say, Bears Say
Bulls Say
Cash Flow TurnaroundA full-year return to positive operating and free cash flow materially improves near-term liquidity and reduces immediate financing need. If sustained, it enables ongoing R&D and commercial support without frequent external capital, lowering dilution risk and increasing runway for strategic execution.
Repaired Equity PositionRestoring equity after a prior deficit reduces insolvency risk and improves the company's ability to access credit or partner financing. This stronger capital base supports operational stability and gives management more flexibility to pursue commercialization or licensing opportunities over the medium term.
Established Specialty Pharma Commercial ModelAn established commercial footprint and drug delivery/formulation capabilities provide recurring revenue potential and competitive differentiation. A focused specialty pharma model and U.S. presence support payer relationships and product launch capability, underpinning sustainable revenue generation if pipeline execution returns to traction.
Bears Say
Severe Revenue DeclineA near-total revenue collapse destroys scale economics, reducing bargaining power with payers and distributors and limiting funds for R&D and commercialization. Restoring meaningful top-line requires durable demand recovery or new product wins; otherwise fixed costs and operational leverage will remain a structural drag.
Deep Negative MarginsExtremely negative margins indicate severe cost or write-down issues and make current operations economically unsustainable. Even with improved cash flow, persistent margin deficits will erode equity and limit the firm's ability to reinvest in growth, forcing restructuring or asset sales if not corrected.
Balance Sheet Volatility & Prior High LeverageA history of negative equity and extreme leverage raises refinancing risk and increases cost of capital. Such volatility undermines long-term financial flexibility, can hamper partnerships or licensing deals, and leaves the company exposed to adverse shocks despite the recent repair in 2025.
Orexo AB News
ORXOF FAQ
What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest stock price was $1.08 and its highest was $4.09 in the past 12 months.
What is Orexo AB’s market cap?
Orexo AB’s market cap is $94.29M.
When is Orexo AB’s upcoming earnings report date?
Orexo AB’s upcoming earnings report date is Apr 28, 2026 which is in 50 days.
How were Orexo AB’s earnings last quarter?
Orexo AB released its earnings results on Feb 05, 2026. The company reported -$0.139 earnings per share for the quarter, missing the consensus estimate of -$0.033 by -$0.106.
Is Orexo AB overvalued?
According to Wall Street analysts Orexo AB’s price is currently Overvalued.
Does Orexo AB pay dividends?
Orexo AB does not currently pay dividends.
What is Orexo AB’s EPS estimate?
Orexo AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Orexo AB have?
Orexo AB has 34,710,640 shares outstanding.
What happened to Orexo AB’s price movement after its last earnings report?
Orexo AB reported an EPS of -$0.139 in its last earnings report, missing expectations of -$0.033. Following the earnings report the stock price went down -7.963%.
Which hedge fund is a major shareholder of Orexo AB?
Currently, no hedge funds are holding shares in ORXOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
ORXOF Company Deck
ORXOF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant R&D progress and strategic developments, such as the BARDA partnership for OX390 and positive growth in the U.S. commercial segment. However, financial challenges remain, including negative EBITDA, revenue declines in the U.S. commercial business, and market uncertainties for OX640. Despite these challenges, strategic initiatives and partnerships indicate potential for future growth.View all ORXOF earnings summariesTechnical Analysis
AlzeCure Pharma AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enzymatica AB
―
Enorama Pharma AB
―